These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3783595)

  • 1. 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues.
    Glennon RA; Slusher RM; Lyon RA; Titeler M; McKenney JD
    J Med Chem; 1986 Nov; 29(11):2375-80. PubMed ID: 3783595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists.
    Glennon RA; Young R; Rosecrans JA
    Eur J Pharmacol; 1983 Jul; 91(2-3):189-96. PubMed ID: 6617740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
    Glennon RA; McKenney JD; Lyon RA; Titeler M
    J Med Chem; 1986 Feb; 29(2):194-9. PubMed ID: 3950904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT2 agonist radioligand.
    Titeler M; Lyon RA; Davis KH; Glennon RA
    Biochem Pharmacol; 1987 Oct; 36(19):3265-71. PubMed ID: 3663239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mCPP but not TFMPP is an antagonist at cardiac 5HT3 receptors.
    Robertson DW; Bloomquist W; Wong DT; Cohen ML
    Life Sci; 1992; 50(8):599-605. PubMed ID: 1736030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin-antagonist effects of 1-(1-naphthyl)piperazine on operant behavior of squirrel monkeys.
    McKearney JW
    Neuropharmacology; 1989 Aug; 28(8):817-21. PubMed ID: 2779752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminative stimulus properties of the serotonin agonist 1-(3-trifluoromethylphenyl)piperazine (TFMPP).
    Glennon RA; McKenney JD; Young R
    Life Sci; 1984 Oct; 35(14):1475-80. PubMed ID: 6482668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible 5-hydroxytryptamine1 (5-HT1) receptor involvement in the stimulus properties of 1-(m-trifluoromethylphenyl)piperazine (TFMPP).
    Cunningham KA; Appel JB
    J Pharmacol Exp Ther; 1986 May; 237(2):369-77. PubMed ID: 2939233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Properties of some 1-arylpiperazines as antagonists of stereotyped behaviors mediated by central serotonergic receptors in rodents.
    Simansky KJ; Schechter LE
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1073-81. PubMed ID: 3144595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine.
    Fiorella D; Helsley S; Rabin RA; Winter JC
    Psychopharmacology (Berl); 1995 Dec; 122(3):237-43. PubMed ID: 8748393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study.
    Glennon RA; Ismaiel AE; McCarthy BG; Peroutka SJ
    Eur J Pharmacol; 1989 Sep; 168(3):387-92. PubMed ID: 2583244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist.
    Ismaiel AM; De Los Angeles J; Teitler M; Ingher S; Glennon RA
    J Med Chem; 1993 Aug; 36(17):2519-25. PubMed ID: 8355253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors.
    Winter JC; Filipink RA; Timineri D; Helsley SE; Rabin RA
    Pharmacol Biochem Behav; 2000 Jan; 65(1):75-82. PubMed ID: 10638639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic studies on DOM as a discriminative stimulus.
    Glennon RA; Hauck AE
    Pharmacol Biochem Behav; 1985 Dec; 23(6):937-41. PubMed ID: 2934750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TFMPP may produce its stimulus effects via a 5-HT1B mechanism.
    McKenney JD; Glennon RA
    Pharmacol Biochem Behav; 1986 Jan; 24(1):43-7. PubMed ID: 3945665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites.
    Friedman RL; Barrett RJ; Sanders-Bush E
    J Pharmacol Exp Ther; 1984 Mar; 228(3):628-35. PubMed ID: 6707913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of imipramine and serotonin-2 agonists and antagonists on serotonin-2 and beta-adrenergic receptors following noradrenergic or serotonergic denervation.
    Eison AS; Eison MS; Yocca FD; Gianutsos G
    Life Sci; 1989; 44(19):1419-27. PubMed ID: 2785627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents.
    Glennon RA; Titeler M; McKenney JD
    Life Sci; 1984 Dec; 35(25):2505-11. PubMed ID: 6513725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl)piperazine.
    Herndon JL; Pierson ME; Glennon RA
    Pharmacol Biochem Behav; 1992 Nov; 43(3):739-48. PubMed ID: 1333084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
    Lyon RA; Titeler M; McKenney JD; Magee PS; Glennon RA
    J Med Chem; 1986 May; 29(5):630-4. PubMed ID: 3701781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.